Recent advances in the development of small-molecule inhibitors for the treatment of acute myeloid leukemia

Current Opinion in Hematology

Volumn 12, Issue 1, 2005, Pages 55-61

  Levis, Mark ^a,b  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b CRB   (United States)

Author keywords

Acute myeloid leukemia; Farnesyltransferase; FLT3; Heat shock protein 90; Map kinase; Ras; Tyrosine kinase

Indexed keywords

2 (2 CHLORO 4 IODOANILINO) N CYCLOPROPYLMETHOXY 3,4 DIFLUOROBENZAMIDE; 4 [6 METHOXY 7 [3 (1 PIPERIDINYL)PROPOXY] 4 QUINAZOLINYL] 1 PIPERAZINECARBOXYLIC ACID (4 ISOPROPOXYPHENYL)AMIDE; CEP 701; CYTARABINE; DAUNORUBICIN; GELDANAMYCIN; HEAT SHOCK PROTEIN 90; IMATINIB; K RAS PROTEIN; MIDOSTAURIN; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN FARNESYLTRANSFERASE INHIBITOR; PROTEIN TYROSINE KINASE; RAS PROTEIN; SEMAXANIB; SUNITINIB; TIPIFARNIB;

ACUTE GRANULOCYTIC LEUKEMIA; APOPTOSIS; BONE MARROW SUPPRESSION; CLINICAL TRIAL; CYTOTOXICITY; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; MYELODYSPLASTIC SYNDROME; PRIORITY JOURNAL; PROTEIN PROCESSING; REVIEW; SIGNAL TRANSDUCTION;

ANTINEOPLASTIC AGENTS; DRUG DESIGN; ENZYME INHIBITORS; HUMANS; LEUKEMIA, MYELOCYTIC, ACUTE; MITOGEN-ACTIVATED PROTEIN KINASES; MODELS, BIOLOGICAL; MUTATION; PROTEIN-TYROSINE KINASES; RAS PROTEINS; SIGNAL TRANSDUCTION;

EID: 13244284844     PISSN: 10656251     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.moh.0000148761.23036.e6     Document Type: Review

References (56)

1. Lowenberg B, Downing JR, Burnett A: Acute myeloid leukemia. N Engl J Med 1999, 341:1051-1062.
2. Tallman MS, Nabhan C, Feusner JH, Rowe JM: Acute promyelocytic leukemia: evolving therapeutic strategies. Blood 2002, 99:759-767.
3. Radich JP, Kopecky KJ, Willman CL, et al.: N-ras mutations in adult de novo acute myelogenous leukemia: prevalence and clinical significance. Blood 1990, 78:801-807.
4. Le DT, Shannon KM: Ras processing as a therapeutic target in hematologic malignancies. Curr Opin Hematol 2002, 9:308-315.
5. Dorrell C, Takenaka K, Minden MD, et al.: Hematopoietic cell fate and the initiation of leukemic properties in primitive primary human cells are influenced by Ras activity and farnesyltransferase inhibition. Mol Cell Biol 2004, 24:6993-7002. This is an important study addressing the role of H-Ras and the effects of FTIs on leukemia stem cells. The authors suggest that different levels of Ras activity in a stem cell, as modulated by an FTI, may have very different effects.
6. Karp JE, Lancet JE, Kaufmann SH, et al.: Clinical and biologic activity of the farnesyltransferase inhibitor R1 15777 in adults with refractory and relapsed acute leukemias: a phase 1 clinical-laboratory correlative trial. Blood 2001, 97:3361-3369.
7. Kurzrock R, Kantarjian HM, Cortes JE, et al.: Farnesyltransferase inhibitor R1 15777 in myelodysplastic syndrome: clinical and biologic activities in the phase 1 setting. Blood 2003, 102:4527-4534. Modest responses are seen when MDS patients are treated with an FTI, with no correlation between response and inhibition of the target.
8. Kurzrock R, Albitar M, Cortes JE, et al.: Phase II study of R1 15777, a farnesyl transferase inhibitor, in myelodysplastic syndrome. J Clin Oncol 2004, 22:1287-1292. Like the phase 1 study, only modest clinical activity is seen in MDS, with no clear mechanism of action.
9. Liesveld JL, Lancet JE, Rosell KE, et al.: Effects of the farnesyl transferase inhibitor R1 15777 on normal and leukemic hematopoiesis. Leukemia 2003, 17:1806-1812. This work suggests that R1 15777 has little significant impact on the leukemia stem cell.
10. Davies H, Bignell GR, Cox C, et al.: Mutations of the BRAF gene in human cancer. Nature 2002, 417:949-954.
11. Mercer KE, Pritchard CA: Raf proteins and cancer: B-Raf is identified as a mutational target. Biochim Biophys Acta 2003, 1653:25-40.
12. Wan PT, Garnett MJ, Roe SM, et al.: Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell 2004, 116:855-867.
13. Lyons JF, Wilhelm S, Hibner B, Bollag G: Discovery of a novel Raf kinase inhibitor. Endocr Relat Cancer 2001, 8:219-225.
14. Smith ML, Snaddon J, Neat M, et al.: Mutation of BRAF is uncommon in AML FAB type M1 and M2. Leukemia 2003, 17:274-275.
15. Lee JW, Soung YH, Park WS, et al.: BRAF mutations in acute leukemias. Leukemia 2004, 18:170-172.
16. Allen LF, Sebolt-Leopold J, Meyer MB: CI-1040 (PD184352), a targeted signal transduction inhibitor of MEK (MAPKK). Semin Oncol 2003, 30:105-116.
17. Sebolt-Leopold JS: MEK inhibitors: a therapeutic approach to targeting the Ras-MAP kinase pathway in tumors. Curr Pharm Des 2004, 10:1907-1914.
18. Druker BJ, Talpaz M, Resta DJ, et al.: Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001, 344:1031-1037.
19. Kindler T, Breitenbuecher F, Marx A, et al.: Efficacy and safety of imatinib in adult patients with c-kit-positive acute myeloid leukemia. Blood 2004, 103:3644-3654. While the responses seen in this study are uncommon, they can be dramatic and relatively durable.
20. Lyman SD, Jacobsen SE: c-Kit ligand and Flt3 ligand: stem/progenitor cell factors with overlapping yet distinct activities. Blood 1998, 91:1101-1134.
21. Nakao M, Yokota S, Iwai T, et al.: Internal tandem duplication of the flt3 gene found in acute myeloid leukemia. Leukemia 1996, 10:1911-1918.
22. Levis M, Small D: FLT3: ITDoes matter in leukemia. Leukemia 2003, 17:1738-1752. An up-to-date review of FLT3 and its validation as a therapeutic target in AML.
23. Gilliland DG, Griffin JD: The roles of FLT3 in hematopoiesis and leukemia. Blood 2002, 100:1532-1542.
24. Kottaridis PD, Gale RE, Frew ME, et al.: The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials. Blood 2001, 98:1752-1759.
25. Kiyoi H, Towatari M, Yokota S, et al.: Internal tandem duplication of the FLT3 gene is a novel modality of elongation mutation which causes constitutive activation of the product. Leukemia 1998, 12:1333-1337.
26. Kiyoi H, Ohno R, Ueda R, et al.: Mechanism of constitutive activation of FLT3 with internal tandem duplication in the juxtamembrane domain. Oncogene 2002, 21:2555-2563.
27. Griffith J, Black J, Faerman C, et al.: The structural basis for autoinhibition of FLT3 by the juxtamembrane domain. Mol Cell 2004, 13:169-178. This important crystallography study provides the first direct data pertaining to the mechanism whereby FLT3/ITD mutations constitutively activate the receptor. This potentially will allow for future refinements of small-molecule inhibitors of FLT3.
28. Levis M, Small D: Small molecule FLT3 tyrosine kinase inhibitors. Curr Pharm Des 2004, 10:1183-1193. A current review of the rather large number of small-molecule FLT3 inhibitors in development.
29. Fiedler W, Mesters R, Tinnefeld H, et al.: A phase II clinical study of SU5416 in patients with refractory acute myeloid leukemia. Blood 2003, 102:2763-2767. One of the first clinical trials of a small-molecule inhibitor in AML Unfortunately, very few useful correlative data were provided.
30. Giles FJ, Cooper MA, Silverman L, et al.: Phase II study of SU5416 - a small-molecule, vascular endothelial growth factor tyrosine-kinase receptor inhibitor - in patients with refractory myeloproliferative diseases. Cancer 2003, 97:1920-1928. While the results of this clinical trial were similar to a simultaneous trial being conducted, a follow-up publication provided the correlative data to explain the lack of significant benefit.
31. O'Farrell AM, Yuen HA, Smolich B, et al.: Effects of SU5416, a small molecule tyrosine kinase receptor inhibitor, on FLT3 expression and phosphorylation in patients with refractory acute myeloid leukemia. Leuk Res 2004, 28:679-689. A correlative study performed on patient samples from the phase 2 trial. This study showed that, while FLT3 was successfully inhibited in vivo in patients receiving drug, the inhibition was not likely sustained, which would predict for a lack of clinical effect.
32. O'Farrell AM, Foran JM, Fiedler W, et al.: An innovative phase I clinical study demonstrates inhibition of FLT3 phosphorylation by SU11248 in acute myeloid leukemia patients. Clin Cancer Res 2003, 9:5465-5476. While the purpose of this trial was to determine a dose for phase 2 study, target inhibition, not maximum tolerated dose, was the primary endpoint, making this a truly innovative study.
33. Yee KW, Schittenhelm M, O'Farrell AM, et al.: Synergistic effect of SU11248 with cytarabine or daunorubicin on FLT3-ITD positive leukemic cells. Blood 2004, in press. Epub ahead of print.
34. George DJ, Dionne CA, Jani J, et al.: Sustained in vivo regression of Dunning H rat prostate cancers treated with combinations of androgen ablation and Trk tyrosine kinase inhibitors, CEP-751 (KT-6587) or CEP-701 (KT-5555). Cancer Res 1999, 59:2395-2401.
35. Levis M, Allebach J, Tse KF, et al.: A FLT3-targeted tyrosine kinase inhibitor is cytotoxic to leukemia cells in vitro and in vivo. Blood 2002, 99:3885-3891.
36. Smith BD, Levis M, Beran M, et al.: Single-agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia. Blood 2004, 103:3669-3676. The first phase 2 trial of an FLT3 inhibitor in AML patients harboring FLT3 mutations. Although clinical responses were modest, they were well correlated with target inhibition in vivo.
37. Brown P, Meshinchi S, Levis M, et al.: Pediatric AML primary samples with FLT3/ITD mutations are preferentially killed by FLT3 inhibition. Blood 2004, 104:1841-1849. The first report of in vitro cytotoxic effects of an FLT3 inhibitor on pediatric AML samples.
38. Levis M, Pham R, Smith BD, Small D: In vitro studies of a FLT3 inhibitor combined with chemotherapy: sequence of administration is important to achieve synergistic cytotoxic effects. Blood 2004, 104:1145-1150. This paper reports an attempt to design a regimen combining chemotherapy with an FLT3 inhibitor using an in vitro model system. CEP-701 is expected to work best when administered simultaneously or immediately following chemotherapy, but not before chemotherapy.
39. Weisberg E, Boulton C, Kelly LM, et al.: Inhibition of mutant FLT3 receptors in leukemia cells by the small molecule tyrosine kinase inhibitor PKC412. Cancer Cell 2002, 1:433-443.
40. Stone RM, DeAngelo DJ, Klimek V, et al.: (2004) Acute myeloid leukemia patients with an activating mutation in FLT3 respond to a small molecule FLT3 tyrosine kinase inhibitor, PKC412. Blood 2004, in press. Epub ahead of print. A second phase 2 trial of an FLT3 inhibitor in FLT3 mutant AML. This study reported significant clinical benefit in 14 of 20 treated patients.
41. Kelly LM, Yu JC, Boulton CL, et al.: CT53518, a novel selective FLT3 antagonist for the treatment of acute myelogenous leukemia (AML). Cancer Cell 2002, 1:421-432.
42. Griswold IJ, Shen LJ, LaRosee P, et al.: Effects of MLN518, a dual FLT3 and KIT inhibitor, on normal and malignant hematopoiesis. Blood 2004, in press. Epub ahead of print. With the recognition that FLT3 inhibitors will be combined with chemotherapy, this study addresses what effects such combination therapy may have on normal hematopoiesis.
43. Shah NP, Nicoll JM, Nagar B, et al.: Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell 2002, 2:117-125.
44. Bagrintseva K, Schwab R, Kohl TM, et al.: Mutations in the tyrosine kinase domain of FLT3 define a new molecular mechanism of acquired drug resistance to PTK inhibitors in FLT3-ITD-transformed hematopoietic cells. Blood 2004, 103:2266-2275.
45. Cools J, Mentens N, Furet P, et al.: Prediction of resistance to small molecule FLT3 inhibitors: implications for molecularly targeted therapy of acute leukemia. Cancer Res 2004, 64:6385-6389. Multiple reports are now appearing anticipating inhibitor-resistant mutations in FLT3.
46. Clark JJ, Cools J, Curley DP, et al.: Variable sensitivity of FLT3 activation loop mutations to the small molecule tyrosine kinase inhibitor MLN518. Blood 2004, 104:2867-2872. Epub ahead of print.
47. Levis M, Tse KF, Smith BD, et al.: A FLT3 tyrosine kinase inhibitor is selectively cytotoxic to acute myeloid leukemia blasts harboring FLT3 internal tandem duplication mutations. Blood 2001, 98:885-887.
48. Ozeki K, Kiyoi H, Hirose Y, et al.: Biologic and clinical significance of the FLT3 transcript level in acute myeloid leukemia. Blood 2004, 103:1901-1908. This report provides evidence supporting the use of FLT3 inhibitors in AML patients with wild-type FLT3.
49. Goetz MP, Toft DO, Ames MM, Erlichman C: The Hsp90 chaperone complex as a novel target for cancer therapy. Ann Oncol 2003, 14:1169-1176.
50. Kamal A, Thao L, Sensintaffar J, et al.: A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors. Nature 2003, 425:407-410.7 This report provides an interesting explanation as to why tumors might be particularly susceptible to Hsp90 inhibitors.
51. Yao Q, Nishiuchi R, Li Q, et al.: FLT3 expressing leukemias are selectively sensitive to inhibitors of the molecular chaperone heat shock protein 90 through destabilization of signal transduction-associated kinases. Clin Cancer Res 2003, 9:4483-4493. A different avenue of attack on aberrant FLT3 signaling is outlined here. This may represent a means to overcoming resistance to FLT3 kinase inhibitors.
52. George P, Bali P, Cohen P, et al.: Cotreatment with 17- allylaminodemethoxygeldanamycin and FLT-3 kinase inhibitor PKC412 is highly effective against human acute myelogenous leukemia cells with mutant FLT-3. Cancer Res 2004, 64:3645-3652. Two small-molecule inhibitors of different proteins converge on the same target: FLT3.
53. Bali P, George P, Cohen P, et al.: Superior activity of the combination of histone deacetylase inhibitor LAQ824 and the FLT-3 kinase inhibitor PKC412 against human acute myelogenous leukemia cells with mutant FLT-3. Clin Cancer Res 2004, 10:4991-4997. Yet another means of molecularly targeting FLT3, by inducing its acetylation, is synergistic in vitro with an FLT3 kinase inhibitor.
54. Bonnet D, Dick JE: Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med 1997, 3:730-737.
55. Reya T, Morrison SJ, Clarke MF, Weissman IL: Stem cells, cancer, and cancer stem cells. Nature 2001, 414:105-111.
56. Hope KJ, Jin L, Dick JE: Acute myeloid leukemia originates from a hierarchy of leukemic stem cell classes that differ in self-renewal capacity. Nat Immunol 2004, 5:738-743. This report does not describe an inhibitor but rather the problem in AML, ie, of the existence of heterogeneous leukemia stem cells within a given patient. Any targeted approach in AML therapy will likely have to impact this cell population in order to be successful.